{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:01:11Z","timestamp":1781629271767,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R24-AG073199"],"award-info":[{"award-number":["R24-AG073199"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30-AG049638"],"award-info":[{"award-number":["P30-AG049638"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P40-OD010965"],"award-info":[{"award-number":["P40-OD010965"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease is characterized by the deposition of amyloid-beta (A\u03b2) plaques, necessitating early detection and reliable biomarkers for effective intervention. Non-human primates, particularly aged vervet monkeys, offer valuable models for studying age-related A\u03b2 pathology due to their close phylogenetic relationship to humans and similar neuropathological features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study assessed the utility of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FC119S, a novel A\u03b2-targeting PET radiotracer, in aged vervet monkeys. The radiochemistry of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FC119S was optimized and automated to ensure high radiochemical purity and molar activity. PET\/MRI imaging was performed to evaluate tracer uptake, distribution, and washout kinetics. Correlations between [\n                      <jats:sup>18<\/jats:sup>\n                      F]FC119S uptake and cerebrospinal fluid (CSF) and plasma biomarkers\u2014including A\u03b2\n                      <jats:sub>42\/40<\/jats:sub>\n                      ratio, pTau181, neurofilament light chain (NfL), and pTau181\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio\u2014were analyzed. Autoradiography was conducted to validate regional tracer binding in brain tissues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FC119S demonstrated high brain uptake, rapid washout, and widespread cortical distribution in vervet monkeys, mirroring patterns observed in human studies. Tracer uptake showed negative associations with CSF A\u03b2\n                      <jats:sub>42\/40<\/jats:sub>\n                      ratio in A\u03b2-affected regions, and significant positive correlations with CSF pTau181 and CSF pTau181\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio in the temporal lobe. Additionally, significant positive correlations were observed between [\n                      <jats:sup>18<\/jats:sup>\n                      F]FC119S uptake and CSF NfL in the anterior cingulate gyrus, parietal, and occipital lobes. Autoradiography confirmed elevated tracer binding in specific brain regions of older vervets with low CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      compared to younger counterparts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings validate [\n                      <jats:sup>18<\/jats:sup>\n                      F]FC119S as a promising PET radiotracer for tracking A\u03b2 deposition in aged vervet monkeys. Its imaging characteristics and biomarker correlations support its translational potential for Alzheimer\u2019s disease research and early diagnostic applications.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-07642-5","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:47:35Z","timestamp":1767844055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PET imaging utility of a novel A\u03b2-tracking PET radiotracer, [18F]FC119S in aged vervet monkeys"],"prefix":"10.1186","volume":"24","author":[{"given":"Bhuvanachandra","family":"Bhoopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett M.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Bansode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna K.","family":"Gollapelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Barcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel N.","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Damuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney L.","family":"Sutphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Craft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Register","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Whitlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Shively","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-5169","authenticated-orcid":false,"given":"Kiran K.","family":"Solingapuram Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"7642_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/7854_2011_168","volume":"11","author":"RW Gould","year":"2012","unstructured":"Gould RW, Porrino LJ, Nader MA. Nonhuman primate models of addiction and PET imaging: dopamine system dysregulation. Curr Top Behav Neurosci. 2012;11:25\u201344.","journal-title":"Curr Top Behav Neurosci"},{"issue":"2","key":"7642_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond E, Wisniewski T. Alzheimer\u2019s disease: experimental models and reality. Acta Neuropathol. 2017;133(2):155\u201375.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"7642_CR3","first-page":"1423","volume":"138","author":"MB Podlisny","year":"1991","unstructured":"Podlisny MB, Tolan DR, Selkoe DJ. Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer\u2019s disease. Am J Pathol. 1991;138(6):1423\u201335.","journal-title":"Am J Pathol"},{"issue":"1","key":"7642_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jalz.2018.06.3057","volume":"15","author":"CS Latimer","year":"2019","unstructured":"Latimer CS, Shively CA, Keene CD, Jorgensen MJ, Andrews RN, Register TC, et al. A nonhuman primate model of early Alzheimer\u2019s disease pathologic change: implications for disease pathogenesis. Alzheimer\u2019s Dement. 2019;15(1):93\u2013105.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"7642_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17460441.2017.1271320","volume":"12","author":"D Van Dam","year":"2017","unstructured":"Van Dam D, De Deyn PP. Non human primate models for Alzheimer\u2019s disease-related research and drug discovery. Expert Opin Drug Discov. 2017;12(2):187\u2013200.","journal-title":"Expert Opin Drug Discov"},{"key":"7642_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fnins.2015.00064","volume":"9","author":"J-M Verdier","year":"2015","unstructured":"Verdier J-M, Acquatella I, Lautier C, Devau G, Trouche S, Lasbleiz C, et al. Lessons from the analysis of nonhuman primates for Understanding human aging and neurodegenerative diseases. Front NeuroSci. 2015;9:64.","journal-title":"Front NeuroSci"},{"key":"7642_CR7","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2741\/1370","volume":"9","author":"M Voytko","year":"2004","unstructured":"Voytko M, Tinkler G. Cognitive function and its neural mechanisms in nonhuman primate models of aging, Alzheimer disease, and menopause. Front Biosci. 2004;9:1899\u2013914.","journal-title":"Front Biosci"},{"issue":"1060","key":"7642_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/postgradmedj-2013-201515rep","volume":"90","author":"BJ Gilbert","year":"2014","unstructured":"Gilbert BJ, Republished. The role of amyloid \u03b2 in the pathogenesis of Alzheimer\u2019s disease. Postgrad Med J. 2014;90(1060):113\u20137.","journal-title":"Postgrad Med J"},{"issue":"1","key":"7642_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"MP Murphy","year":"2010","unstructured":"Murphy MP, LeVine H. 3rd. Alzheimer\u2019s disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311\u201323.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"7642_CR10","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","volume":"41","author":"S Landau","year":"2014","unstructured":"Landau S, Thomas B, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41(7):1398\u2013407.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7642_CR11","doi-asserted-by":"crossref","unstructured":"Moghbel MC, Saboury B, Basu S, Metzler SD, Torigian DA, L\u00e5ngstr\u00f6m B, et al. Amyloid-\u03b2 imaging with PET in Alzheimer\u2019s disease: is it feasible with current radiotracers and technologies? Springer; 2012.","DOI":"10.1007\/s00259-011-1960-4"},{"issue":"4","key":"7642_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","volume":"6","author":"N Okamura","year":"2018","unstructured":"Okamura N, Harada R, Ishiki A, Kikuchi A, Nakamura T, Kudo Y. The development and validation of Tau PET tracers: current status and future directions. Clin Translational Imaging. 2018;6(4):305\u201316.","journal-title":"Clin Translational Imaging"},{"key":"7642_CR13","doi-asserted-by":"crossref","unstructured":"Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer\u2019s disease. Biochim Biophys Acta Mol Basis Dis. 2012;1822(3):370\u20139.","DOI":"10.1016\/j.bbadis.2011.11.005"},{"issue":"9","key":"7642_CR14","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1021\/acs.molpharmaceut.7b00351","volume":"14","author":"SJ Oh","year":"2017","unstructured":"Oh SJ, Kim MH, Han SJ, Kang KJ, Ko IO, Kim Y, et al. Preliminary PET study of 18F-FC119S in normal and Alzheimer\u2019s disease models. Mol Pharm. 2017;14(9):3114\u201320.","journal-title":"Mol Pharm"},{"issue":"12","key":"7642_CR15","doi-asserted-by":"publisher","first-page":"e6441","DOI":"10.1097\/MD.0000000000006441","volume":"96","author":"BH Byun","year":"2017","unstructured":"Byun BH, Kim BI, Park SY, Ko IO, Lee KC, Kim KM, et al. Head-to-head comparison of 11\u00a0C-PiB and 18F-FC119S for A\u03b2 imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer\u2019s disease patients. Med (Baltim). 2017;96(12):e6441\u2013e.","journal-title":"Med (Baltim)"},{"issue":"9","key":"7642_CR16","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.bmc.2016.03.034","volume":"24","author":"BS Lee","year":"2016","unstructured":"Lee BS, Chu SY, Kwon HR, Park C, Sirion U, Brockschnieder D, et al. Synthesis and evaluation of 6-(3-[18F]fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging A\u03b2 plaques. Bioorg Med Chem. 2016;24(9):2043\u201352.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"7642_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cpet.2009.12.008","volume":"5","author":"VL Villemagne","year":"2010","unstructured":"Villemagne VL, Rowe CC. Amyloid PET ligands for dementia. PET Clin. 2010;5(1):33\u201353.","journal-title":"PET Clin"},{"issue":"7","key":"7642_CR18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00213-013-3329-9","volume":"231","author":"CA Shively","year":"2014","unstructured":"Shively CA, Register TC, Higley JD, Willard SL. Sertraline effects on cerebrospinal fluid monoamines and species-typical socioemotional behavior of female cynomolgus monkeys. Psychopharmacology. 2014;231(7):1409\u201316.","journal-title":"Psychopharmacology"},{"issue":"1","key":"7642_CR19","doi-asserted-by":"publisher","first-page":"e12284","DOI":"10.1002\/trc2.12284","volume":"8","author":"BM Frye","year":"2022","unstructured":"Frye BM, Craft S, Register TC, Kim J, Whitlow CT, Barcus RA, et al. Early Alzheimer\u2019s disease-like reductions in Gray matter and cognitive function with aging in nonhuman primates. Alzheimers Dement (N Y). 2022;8(1):e12284.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"20","key":"7642_CR20","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1021\/acschemneuro.3c00527","volume":"14","author":"B Bhoopal","year":"2023","unstructured":"Bhoopal B, Gollapelli KK, Damuka N, Miller M, Krizan I, Bansode A, et al. Preliminary PET imaging of Microtubule-Based PET radioligand [11\u00a0C]MPC-6827 in a nonhuman primate model of Alzheimer\u2019s disease. ACS Chem Neurosci. 2023;14(20):3745\u201351.","journal-title":"ACS Chem Neurosci"},{"key":"7642_CR21","doi-asserted-by":"publisher","first-page":"113937","DOI":"10.1016\/j.biopha.2022.113937","volume":"156","author":"N Damuka","year":"2022","unstructured":"Damuka N, Bashetti N, Mintz A, Bansode AH, Miller M, Krizan I, et al. [18F]KS1, a novel ascorbate-based ligand images ROS in tumor models of rodents and nonhuman primates. Biomed Pharmacother. 2022;156:113937.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7642_CR22","doi-asserted-by":"publisher","first-page":"100245","DOI":"10.1016\/j.ynirp.2025.100245","volume":"5","author":"N Damuka","year":"2025","unstructured":"Damuka N, Schaaf GW, Miller M, Bradley C, Bhoopal B, Krizan I, et al. Radiation-induced brain injury in non-human primates: A dual tracer PET study with [11\u00a0C]MPC-6827 and [11\u00a0C]PiB. NeuroImage: Rep. 2025;5(1):100245.","journal-title":"NeuroImage: Rep"},{"issue":"13","key":"7642_CR23","doi-asserted-by":"publisher","first-page":"9120","DOI":"10.1021\/acs.jmedchem.3c00720","volume":"66","author":"AH Bansode","year":"2023","unstructured":"Bansode AH, Damuka N, Bashetti N, Gollapelli KK, Krizan I, Bhoopal B, et al. First GPR119 PET imaging ligand: Synthesis, Radiochemistry, and preliminary evaluations. J Med Chem. 2023;66(13):9120\u20139.","journal-title":"J Med Chem"},{"issue":"2","key":"7642_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s43440-025-00695-9","volume":"77","author":"KK Gollapelli","year":"2025","unstructured":"Gollapelli KK, Krizan I, Bhoopal B, Damuka N, Moriarty C, Miller M, et al. [11\u00a0C]MK-6884 PET imaging reveals lower M4 muscarinic acetylcholine receptor availability following cocaine self-administration in male rats. Pharmacol Rep. 2025;77(2):532\u201341.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"7642_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13311-016-0481-z","volume":"14","author":"SE Counts","year":"2017","unstructured":"Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the early detection and progression of Alzheimer\u2019s disease. Neurotherapeutics. 2017;14(1):35\u201353.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"7642_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.24454","volume":"78","author":"BW Patterson","year":"2015","unstructured":"Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015;78(3):439\u201353.","journal-title":"Ann Neurol"},{"key":"7642_CR27","doi-asserted-by":"crossref","unstructured":"Chiotis K, Carter SF, Farid K, Savitcheva I, Nordberg A; for the Diagnostic Molecular Imaging Group, et al. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. Eur J Nucl Med Mol Imaging. 2015;42(10):1492\u2013506.","DOI":"10.1007\/s00259-015-3115-5"},{"key":"7642_CR28","doi-asserted-by":"crossref","unstructured":"Byun BH, Kim BI, Park SY, Ko IO, Lee KC, Kim KM, et al. Head-to-head comparison of 11\u00a0C-PiB and 18F-FC119S for A\u03b2 imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer\u2019s disease patients. Medicine. 2017;96(12).","DOI":"10.1097\/MD.0000000000006441"},{"key":"7642_CR29","doi-asserted-by":"crossref","unstructured":"Dorey A, Perret-Liaudet A, Tholance Y, Fourier A, Quadrio I. Cerebrospinal fluid A\u03b240 improves the interpretation of A\u03b242 concentration for diagnosing Alzheimer\u2019s disease. Front Neurol. 2015;6.","DOI":"10.3389\/fneur.2015.00247"},{"issue":"4","key":"7642_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of \u03b2-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Ann Neurol. 1995;38(4):643\u20138.","journal-title":"Ann Neurol"},{"issue":"6","key":"7642_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid \u03b2-Amyloid(1\u201342) in Alzheimer disease: differences between Early- and Late-Onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673\u201380.","journal-title":"Arch Neurol"},{"issue":"3","key":"7642_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1046\/j.1471-4159.2002.00818.x","volume":"81","author":"J Wiltfang","year":"2002","unstructured":"Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated A\u03b2 peptides 1\u201337\/38\/39 in addition to 1\u201340\/42 in Alzheimer\u2019s disease and in patients with chronic neuroinflammation. J Neurochem. 2002;81(3):481\u201396.","journal-title":"J Neurochem"},{"issue":"2","key":"7642_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","volume":"51","author":"A Olsson","year":"2005","unstructured":"Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg Br, et al. Simultaneous measurement of \u03b2-Amyloid(1\u201342), total Tau, and phosphorylated Tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336\u201345.","journal-title":"Clin Chem"},{"key":"7642_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2022.03.005","volume":"115","author":"MR LaPoint","year":"2022","unstructured":"LaPoint MR, Baker SL, Landau SM, Harrison TM, Jagust WJ. Rates of \u03b2-amyloid deposition indicate widespread simultaneous accumulation throughout the brain. Neurobiol Aging. 2022;115:1\u201311.","journal-title":"Neurobiol Aging"},{"issue":"12","key":"7642_CR35","doi-asserted-by":"publisher","first-page":"e1917126","DOI":"10.1001\/jamanetworkopen.2019.17126","volume":"2","author":"JJ Llibre-Guerra","year":"2019","unstructured":"Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, et al. Association of longitudinal changes in cerebrospinal fluid total Tau and phosphorylated Tau 181 and brain atrophy with disease progression in patients with Alzheimer disease. JAMA Netw Open. 2019;2(12):e1917126\u2013e.","journal-title":"JAMA Netw Open"},{"key":"7642_CR36","doi-asserted-by":"crossref","unstructured":"Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham PL, Fowler C, et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. Alzheimers Dement (Diagn Assess Dis Monit). 2020;12(1):e12005.","DOI":"10.1002\/dad2.12005"},{"issue":"8","key":"7642_CR37","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","volume":"269","author":"G Giacomucci","year":"2022","unstructured":"Giacomucci G, Mazzeo S, Bagnoli S, Ingannato A, Leccese D, Berti V, et al. Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022;269(8):4270\u201380.","journal-title":"J Neurol"},{"issue":"3","key":"7642_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau\/\u03b2-Amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343\u20139.","journal-title":"Arch Neurol"},{"key":"7642_CR39","doi-asserted-by":"crossref","unstructured":"Migliaccio R, Cacciamani F. Chapter 25 - The Temporal lobe in typical and atypical Alzheimer disease. In: Miceli G, Bartolomeo P, Navarro V, editors. Handbook of Clinical Neurology. Vol. 187. Elsevier; 2022. pp. 449\u201366.","DOI":"10.1016\/B978-0-12-823493-8.00004-3"},{"key":"7642_CR40","doi-asserted-by":"crossref","unstructured":"Fowler CJ, Stoops E, Rainey-Smith SR, Vanmechelen E, Vanbrabant J, Dewit N, et al. Plasma p-tau181\/A\u03b21\u201342 ratio predicts A\u03b2-PET status and correlates with CSF-p-tau181\/A\u03b21\u201342 and future cognitive decline. Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit. 2022;14(1):e12375.","DOI":"10.1002\/dad2.12375"},{"issue":"4","key":"7642_CR41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"7642_CR42","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1523\/JNEUROSCI.5062-08.2009","volume":"29","author":"RL Buckner","year":"2009","unstructured":"Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer\u2019s disease. J Neurosci. 2009;29(6):1860\u201373.","journal-title":"J Neurosci"},{"issue":"6","key":"7642_CR43","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.neuron.2011.12.040","volume":"73","author":"A Raj","year":"2012","unstructured":"Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73(6):1204\u201315.","journal-title":"Neuron"},{"issue":"6","key":"7642_CR44","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.neuron.2012.03.004","volume":"73","author":"J Zhou","year":"2012","unstructured":"Zhou J, Gennatas Efstathios D, Kramer Joel H, Miller Bruce L. Seeley William W. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73(6):1216\u201327.","journal-title":"Neuron"},{"issue":"20","key":"7642_CR45","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):2031\u20138.","journal-title":"Neurology"},{"issue":"1","key":"7642_CR46","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6(1):26801.","journal-title":"Sci Rep"},{"issue":"1","key":"7642_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14283\/jpad.2018.41","volume":"6","author":"V P\u00e9rez-Grijalba","year":"2019","unstructured":"P\u00e9rez-Grijalba V, Romero J, Pesini P, Sarasa L, Monle\u00f3n I, San-Jos\u00e9 I, et al. Plasma A\u03b242\/40 ratio detects early stages of Alzheimer\u2019s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimer\u2019s Disease. 2019;6(1):34\u201341.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"7642_CR48","doi-asserted-by":"crossref","unstructured":"Wang Y-L, Chen J, Du Z-L, Weng H, Zhang Y, Li R, et al. Plasma p-tau181 level predicts neurodegeneration and progression to Alzheimer\u2019s dementia: a longitudinal study. Front Neurol. 2021;12.","DOI":"10.3389\/fneur.2021.695696"},{"issue":"10","key":"7642_CR49","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/alz.12332","volume":"17","author":"JR Chong","year":"2021","unstructured":"Chong JR, Ashton NJ, Karikari TK, Tanaka T, Saridin FN, Reilhac A, et al. Plasma P-tau181 to A\u03b242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer\u2019s disease patients with concomitant cerebrovascular disease. Alzheimer\u2019s Dement. 2021;17(10):1649\u201362.","journal-title":"Alzheimer\u2019s Dement"},{"key":"7642_CR50","doi-asserted-by":"crossref","unstructured":"Jiao B, Liu H, Guo L, Liao X, Zhou Y, Weng L, et al. Performance of plasma amyloid \u03b2, total tau, and neurofilament light chain in the identification of probable Alzheimer\u2019s disease in South China. Front Aging Neurosci. 2021;13.","DOI":"10.3389\/fnagi.2021.749649"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07642-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07642-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07642-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:17:20Z","timestamp":1781626640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07642-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7642"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07642-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal housing, handling, and experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) at Wake Forest University School of Medicine. Animal environmental enrichment followed IACUC\u2019s Non-Human-Primate Environmental Enrichment Plan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}